News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
296,642 Results
Type
Article (15779)
Company Profile (256)
Press Release (280601)
Multimedia
Podcasts (126)
Webinars (13)
Section
Business (90848)
Career Advice (173)
Deals (13527)
Drug Delivery (69)
Drug Development (51104)
Employer Resources (32)
FDA (6011)
Job Trends (5224)
News (145968)
Policy (10096)
Tag
2025 Best Places to Work (12)
2026 Best Places to Work (18)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 NextGen (1)
2027 Pharm Country Standard (3)
40 Under 40 (4)
Academia (981)
Accelerated approval (39)
ADA (34)
Adcomms (16)
Allergies (128)
Alliances (21778)
ALS (204)
Alzheimer's disease (1258)
Antibody-drug conjugate (ADC) (579)
Approvals (6437)
Artificial intelligence (487)
ASCO (224)
Autoimmune disease (407)
Automation (20)
Bankruptcy (112)
Belgium (29)
Best Places to Work (4559)
BIO (56)
Biologics (69)
BIOSECURE Act (6)
Biosimilars (161)
BioSpace Insights (81)
Biotechnology (179)
Bispecific (49)
Bladder cancer (143)
Brain cancer (72)
Breast cancer (506)
Cancer (5013)
Cardiovascular disease (372)
Career advice (176)
Career pathing (15)
CAR-T (346)
CDC (11)
CDMO (124)
Celiac Disease (4)
Cell therapy (884)
Cervical cancer (31)
Clinical research (46608)
Collaboration (1769)
Commercialization (44)
Company closure (4)
Compensation (980)
Complete response letters (72)
COVID-19 (1158)
CRISPR (131)
CRO (3)
C-suite (1051)
Cystic fibrosis (132)
Data (7592)
Denatured (27)
Depression (134)
Dermatology (131)
Diabetes (404)
Diagnostics (1562)
Digital health (21)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (358)
Drug pricing (55)
Drug shortages (4)
Duchenne muscular dystrophy (342)
Earnings (33917)
Editorial (37)
Employer branding (4)
Employer resources (30)
ESMO (311)
Events (55549)
Executive appointments (804)
Eye disease (16)
FDA (8817)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (36)
Funding (1490)
Gene editing (264)
Generative AI (50)
Gene therapy (721)
GLP-1 (637)
Government (1220)
Grass and pollen (3)
Guidances (182)
Healthcare (6833)
Hematology (141)
HIV (40)
Huntington's disease (75)
Idiopathic pulmonary fibrosis (10)
IgA nephropathy (125)
Immunology and inflammation (290)
Immuno-oncology (121)
Indications (190)
Infectious disease (1340)
Inflammatory bowel disease (215)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (260)
Interviews (22)
IPO (7422)
IRA (13)
Job creations (874)
Job search strategy (140)
JPM (41)
Kidney cancer (13)
Kidney disease (125)
Labor market (44)
Layoffs (279)
Leadership (22)
Legal (1407)
Licensing (92)
Liver cancer (54)
Longevity (39)
Lung cancer (696)
Lung diease (19)
Lymphoma (368)
Machine learning (37)
Management (8)
Manufacturing (709)
Marketing (25)
MASH (188)
Medical affairs (3)
Medical device (2760)
Medtech (2814)
Mergers & acquisitions (6989)
Metabolic disorders (1115)
Middle East (1)
mRNA (227)
Multiple sclerosis (161)
Multispecific (6)
NASH (14)
Netherlands (19)
Neurodegenerative disease (429)
Neuropsychiatric disorders (105)
Neuroscience (2767)
Neurotech (2)
NextGen: Class of 2026 (2042)
Non-profit (895)
Now hiring (49)
Obesity (495)
Opinion (163)
Ovarian cancer (230)
Pain (172)
Pancreatic cancer (306)
Parkinson's disease (365)
Partnered (19)
Patents (507)
Patient advocacy (6)
Patient recruitment (681)
Patient selection (87)
Peanut (55)
People (27968)
Peptides (32)
Pharmaceutical (31)
Pharmacy benefit managers (9)
Phase 1 (16497)
Phase 2 (21687)
Phase 3 (13722)
Pipeline (9164)
Policy (116)
Postmarket research (853)
Preclinical (6967)
Press Release (30)
Prostate cancer (246)
Psychedelics (89)
Radioligand (3)
Radiopharmaceuticals (339)
Rare diseases (1126)
Real estate (1463)
Recruiting (12)
Regenerative medicine (23)
Regulatory (11446)
Reports (33)
Research institute (1008)
Resumes & cover letters (20)
Rett syndrome (51)
RNA editing (38)
RSV (26)
Schizophrenia (175)
Series A (295)
Series B (197)
Service/supplier (1)
Sickle cell disease (110)
Special edition (24)
Spinal muscular atrophy (131)
Sponsored (22)
Startups (2056)
State (1)
Stem cells (7)
Stomach cancer (7)
Substance use disorders (20)
Supply chain (48)
Switzerland (14)
Tariffs (22)
The Weekly (97)
Vaccines (468)
Venture capital (119)
Weight loss (263)
Wet AMD (5)
Women's health (63)
Worklife (4)
Date
Today (86)
Last 7 days (486)
Last 30 days (2311)
Last 365 days (18496)
2026 (16731)
2025 (18097)
2024 (20472)
2023 (22415)
2022 (26814)
2021 (27806)
2020 (23360)
2019 (16231)
2018 (11745)
2017 (13745)
2016 (11847)
2015 (14356)
2014 (10400)
2013 (7491)
2012 (7542)
2011 (7618)
2010 (7433)
Location
Africa (161)
Alabama (86)
Alaska (2)
Arizona (107)
Arkansas (6)
Asia (19313)
Australia (3324)
California (10446)
Canada (2589)
China (1376)
Colorado (394)
Connecticut (394)
Delaware (363)
Europe (41364)
Florida (1372)
Georgia (289)
Hawaii (3)
Idaho (18)
Illinois (653)
India (78)
Indiana (246)
Iowa (13)
Japan (407)
Kansas (92)
Kentucky (13)
Louisiana (18)
Maine (14)
Maryland (1067)
Massachusetts (8342)
Michigan (143)
Minnesota (361)
Mississippi (4)
Missouri (41)
Montana (17)
Nebraska (6)
Nevada (70)
New Hampshire (22)
New Jersey (2349)
New Mexico (14)
New York (2532)
North Carolina (1208)
North Dakota (9)
Northern California (5429)
Ohio (253)
Oklahoma (12)
Oregon (28)
Pennsylvania (1891)
Puerto Rico (12)
Rhode Island (31)
South America (218)
South Carolina (20)
Southern California (4241)
Tennessee (71)
Texas (1498)
United States (34412)
Utah (143)
Virginia (211)
Washington D.C. (37)
Washington State (848)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
296,642 Results for "wren therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Wren Laboratories Unveils Dynamic Executive Leadership Team and 2024 Commercial Strategy Overhaul
Wren Laboratories, a leader in novel in-vitro diagnostic technologies, announced significant enhancements to its executive leadership team.
June 17, 2024
·
5 min read
Genetown
Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases
Wren Therapeutics announced a number of new members to its Scientific Advisory Board.
January 4, 2023
·
3 min read
Genetown
Wren Therapeutics Renamed WaveBreak, Signifying Focus on Stopping the Wave of Neurodegeneration in Parkinson’s Disease, Alzheimer’s Disease, and ALS at its Source
Wren Therapeutics announced today that the company has changed its name to WaveBreak.
April 25, 2023
·
2 min read
Funding
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
November 17, 2026
·
2 min read
·
Gabrielle Masson
Business
Wren Appoints Bart Henderson as Chief Executive Officer
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, announced the appointment of Bart Henderson as Chief Executive Officer.
March 4, 2022
·
2 min read
Press Releases
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
November 16, 2026
·
3 min read
Press Releases
Anacalypsis Therapeutics Raises Pre-Seed Financing Led by Metavallon VC to Advance a First-in-Class Therapeutic Strategy for Parkinson’s Disease
Athens-based biotech will use the financing to advance AT001, its lead therapeutic program targeting the LRRK2–FADD interaction, through a key in vivo efficacy study.
September 21, 2026
·
1 min read
Press Releases
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
October 13, 2026
·
11 min read
Press Releases
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
November 10, 2026
·
5 min read
Press Releases
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November 2026 Investor Conferences
November 5, 2026
·
1 min read
1 of 29,665
Next